未找到相关数据
Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.
被引：0
作者：
Sun, Mingyuan
Qiu, Lugui
Wei, Yongqiang
Jin, Jie
Li, Xin
Liu, Xue
Yin, Shaohong
Qi, Junyuan
机构：
[1] Natl Clin Res Ctr Hematol Disorders, Inst Hematol & Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Co, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Co, Blood Dis Hosp, Tianjin, Peoples R China
[4] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China
[5] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Hangzhou, Zhejiang, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, Dept Hematol, Changsha, Peoples R China
[7] Lunan Pharmaceut Grp Co LTD, Linyi, Shandong, Peoples R China
[8] Chinese Acad Med Sci, Blood Inst, Tianjin, Peoples R China
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8038
引用
收藏
页数：1
相关论文